TuHURA Biosciences, Inc.
NASDAQ:HURA · NASDAQ Capital Market
+$0.13 today
Vol 0.32M · Avg 0.88M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-143.6%
avg -145.3%
ROIC
-145.7%
avg 1476.3%
ROA
-109.9%
avg -186.5%
Analysis
ROA is currently the strongest return metric at -109.9% versus its period average of -186.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
James A. Bianco | President, Chief Executive Officer & Director | $1.12M | — | 69 | $2.17M | 3.41% |
Dan Dearborn | Executive Vice President of Finance & Chief Financial Officer | $544,036.00 | — | 58 | $273,696.00 | 0.43% |
Michael Lawman | Co-Founder | — | — | — | — | — |
Michael Krsulich | Head of Quality Assurance | — | — | — | — | — |
Patricia Lawman | Co-Founder | — | — | — | — | — |
Bertrand Le Bourdonnec | Executive Vice President, Head of Drug Discovery, Early Development, & Program Management | — | — | — | — | — |
Amanda Garofalo | Senior Vice President of Clinical Operations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Opus Genetics, Inc.
NASDAQ:IRD
$328.84M
Spero Therapeutics, Inc.
NASDAQ:SPRO
$165.02M
Acumen Pharmaceuticals, Inc.
NASDAQ:ABOS
$143.56M
Agenus Inc.
NASDAQ:AGEN
$137.42M
Seer, Inc.
NASDAQ:SEER
$94.57M
Cognition Therapeutics, Inc.
NASDAQ:CGTX
$89.03M
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
$58.95M
Seres Therapeutics, Inc.
NASDAQ:MCRB
$55.20M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
VistaGen Therapeutics, Inc.
VTGN
$18.88M
Who manages HURA?
TuHURA Biosciences, Inc. (HURA) lists 7 active executives. The top listed executive is Michael Lawman, Co-Founder.
Are HURA insiders buying or selling?
Recent insider activity shows net buying of $15.55M.
Explore More
Continue the stock analysis
Jump to another research area for this company.